【ChiCTR2500107057】Effectiveness of an immersive virtual reality (VR)-based mindfulness intervention (MI) to reduce depressive symptoms in patients with autoimmune arthritis (AA): a randomized control trial (RCT)
ChiCTR2500107057
尚未开始
/
/
/
2025-08-01
/
/
Autoimmune arthritis
Effectiveness of an immersive virtual reality (VR)-based mindfulness intervention (MI) to reduce depressive symptoms in patients with autoimmune arthritis (AA): a randomized control trial (RCT)
Effectiveness of an immersive virtual reality (VR)-based mindfulness intervention (MI) to reduce depressive symptoms in patients with autoimmune arthritis (AA): a randomized control trial (RCT)
/
To evaluate the effectiveness of an immersive VR-based mindfulness intervention program in reducing depressive symptoms among patients with autoimmune arthritis.
随机平行对照
治疗新技术
Eligible subjects will be individually randomized to the intervention or control group (1:1) using sequentially numbered, opaque, sealed envelopes (SNOSE), and block randomization. A statistician who is not part of the research team will generate the random numbers and assignment and prepare 198 identical opaque sealed A5-sized envelopes. The block randomization list will be created with a 1:1 allocation ratio and block size of 4, 8 and 12 in random order to ensure that a similar number of participants will be allocated to both groups.
Given the apparent nature of the intervention, it is unlikely to blind participants and intervention providers.
The Kadoorie Charitable Foundation Grant & Hong Kong Metropolitan University
/
99
/
2025-01-01
2027-02-28
/
Patients with AA aged 18 or above will be eligible. The inclusion criteria are: 1. being able to communicate in Cantonese, 2. presenting with depressive symptoms over the past two weeks based on the established criteria (DSM V) with a Patient Health Questionniare-9 score of at least five or above, 3. being able to commit to six consecutive weekly VR-based mindfulness sessions, and 4. on a stable medication regimen.;
请登录查看1. Severe visual or auditory deficits. 2. Severe organic disease or malignant tumour. 3. A history of motion or simulator sickness. 4. History of epilepsy. 5. A recent mental disorder in the past 12 months or current psychiatric disorder that are potentially life threatening (i.e. psychosis, suicidal ideation). 6. Meditation and yoga practice within the past 6 months or will plan to start mindfulness intervention.;
请登录查看School of Nursing and Health Sciences, Hong Kong Metropolitan University
/
/
School of Nursing and Health Sciences, Hong Kong Metropolitan University的其他临床试验
School of Nursing and Health Sciences, Hong Kong Metropolitan University的其他临床试验
最新临床资讯
-
Nat Rev Clin Oncol|AI赋能肿瘤临床试验:从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29
